The active GLP1 kit is designed for the accurate quantitative measurement of the glucagon-like peptide-1 active forms on cell supernatants.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein Quantification |
Sample Volume | 10 µL |
The active GLP1 kit is designed for the accurate quantitative measurement of the glucagon-like peptide-1 active forms on cell supernatants.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Active GLP-1, also known as glucagon-like peptide-1 active forms (GLP-1(7-36)NH2, and GLP-1(7-37)), has become a key biomarker in treatment of type 2 diabetes. The main actions of GLP-1 are stimulation of insulin secretion, and inhibition of glucagon secretion and food intake. In vivo, the active forms are rapidly degraded into inactive forms (9-36)NH2 and (9-37) by the dipeptidyl peptidase IV (DPP-IV). The active GLP-1 kit is designed for a rapid detection of GLP-1 in cell supernatants.
Application |
Protein Quantification
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Kit
|
Sample Volume |
10 µL
|
Shipping Conditions |
Shipped in Dry Ice
|
Target Class |
Biomarkers
|
Technology |
TR-FRET
|
Therapeutic Area |
Metabolism/Diabetes
|
Unit Size |
500 Assay Points
|
Active GLP-1 is measured using a sandwich immunoassay involving two antibodies, one labelled with Lumi4Tb-Cryptate (Donor) and the second with d2 (Acceptor). The intensity of the signal is proportional to the concentration of GLP-1 active forms present in the sample.
The active GLP-1 test can be run on cell supernatants using a simple 'addition and read' procedure described on the right (no wash steps). The HTRF conjugates may be pre-mixed and added in a single dispensing step to further streamline the protocol. An assay can be run in 96- to 384-well plates by simply resizing each addition volume proportionally. The active GLP-1 assay protocol is described here, using a white 384-well small volume plate.
Active GLP-1 | |
---|---|
Incubation | ON at RT |
Linear range | 43. 8 to 1,400 pg/mL |
Detection limit | 25 pg/mL* |
Species reactivity | Rat, mouse, human, porcine |
Peptide | Cross reactivity |
---|---|
GLP-1 (7-36) amide | 100% |
GLP-1 (7-37) | 98.04% |
GLP-1 (1-36) amide | 0.39% |
GLP-1 (1-37) | 0.37% |
GLP-1 (9-36) amide | <0.01% |
GLP-1 (7-17) | <0.01% |
GLP-2 | <0.01% |
Glucagon | <0.01% |
Active GLP-1 standard curve was performed in a final 20µL assay volume and read on a Pherastar instrument (BMG LABTECH).
* Caution: all HTRF compatible readers but SpectraMax M5e and FlexStation reach this sensitivity criteria.
As shown below, the active GLP-1 assay correlates well with classical ELISA assay while offering handling easiness and labor time saving. Side-by-side comparison of HTRF and ELISA assays for GLP-1 quantification was run in white 384-w small volume plate using crude NCI-H176 cell supernatants. A correlation factor of 0.97 was obtained (n=6).
HTRF active GLP-1 | Fluorescent ELISA |
---|---|
1 assay step mix and read (no washing) - <1hrs assay time | 6 sequential steps - >4hrs assay time |
Dilutions of the NCI-H716 cell supernatants 1 and 2 were performed using the HTRF assay diluent. GLP-1 concentration was then determined in crude supernatants and in diluted samples (1:2, 1:4, 1:8 and 1:16). Figure on the right indicates the means (+/- SD) of 3 independent experiments. The strong correlations obtained between measured and expected GLP-1 concentrations demonstrate the linearity of dilution within the assay range.
A time-course was determined for active GLP-1 secretion in human enteroendocrine NCI-H716 cells after glucose stimulation. Cells (2.105 cells/well) were seeded into 96-well culture plates pre-coated with Matrigel, and cultured for two days with DMEM 10% FBS medium. On the experiment day, cells were washed and incubated for 2 hours with increasing concentration of glucose in 100 µL of KRB supplemented with DPP IV inhibitor . At the end of glucose stimulation, 10 µL of supernatants were transferred to a 384 small volume-well plate, and assayed for active GLP-1 level as described in 'Assay protocol'. As expected, active GLP-1 was induced with Glucose dose dependence. The maximum amplitude of active GLP-1 triggered by 10% glucose versus basal production was 2.1.
Are you looking for resources, click on the resource type to explore further.
Helping you select an optimal assay for your research
Revvity offers a comprehensive line of insulin quantification assays designed...
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
We are here to answer your questions.